Citadel Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Citadel Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-26,300	Closed	-$8K	–	9612
2018 Q1	$8K	Sell	26,300 -12,000	-31%	-$17.9K	﹤0.01%	8188
2017 Q4	$63K	Buy	+38,300	New	+$65.9K	﹤0.01%	7563
2017 Q2	–	Sell	-1,850	Closed	-$6K	–	8444
2017 Q1	$6K	Sell	1,850 -638	-26%	-$3.02K	﹤0.01%	7352
2016 Q4	$13K	Buy	2,488 +263	+12%	+$4.55K	﹤0.01%	7142
2016 Q3	$56K	Buy	+2,225	New	+$56.1K	﹤0.01%	6832
2016 Q1	–	Sell	-1,313	Closed	-$49K	–	8700
2015 Q4	$49K	Sell	1,313 -1,262	-49%	-$55.7K	﹤0.01%	7335
2015 Q3	$125K	Sell	2,575 -4,463	-63%	-$312K	﹤0.01%	6728
2015 Q2	$485K	Buy	7,038 +6,263	+808%	+$290K	﹤0.01%	5030
2015 Q1	$28K	Buy	775 +575	+288%	+$17K	﹤0.01%	7731
2014 Q4	$3K	Sell	200 -325	-62%	-$4.72K	﹤0.01%	8350
2014 Q3	$8K	Buy	525 +175	+50%	+$3.68K	﹤0.01%	7820
2014 Q2	$9K	Buy	+350	New	+$8.64K	﹤0.01%	7617

Other funds holding ANTH

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citadel Advisors's ANTH Position: Q2 2018 in Review

Citadel Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 35,297 shares — an estimated $11K sold.

Citadel Advisors first reported a position in ANTH in Q2 2014 and held it in 12 quarters. The position peaked at $1.09M in Q3 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

Citadel Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Citadel Advisors sold 35,297 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $11K.
Citadel Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2014 and held it in 12 quarters.
Citadel Advisors's Anthera Pharmaceuticals, Inc. position peaked at $1.09M in Q3 2015.
5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Citadel Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.